The initial success of the copyright undeniably transformed the pharmaceutical landscape, but investing in companies strongly reliant on off-patent versions presents a challenging picture. While early returns were substantial, the cessation of patents and the appearance of less expensive alternatives have weakened the customer base. Thus, a thoroug